A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients
NCT: NCT07839793 · RECRUITING
Brief Summary
Flexilev is a Parkinson's disease medicine made of small, dissolvable tablets containing low doses of levodopa and carbidopa, allowing doses to be adjusted in small, precise steps. OraFID is a new mechanical device that dispenses the exact number of tablets needed, with better than 99% accuracy, in amounts from 1 to 20 tablets. An optional companion app, Levilog, reminds patients when to take their dose and records how much medicine (tablets and milligrams) was taken. This 12-week study will mainly assess how acceptable this treatment routine is and how well patients stick with it when using Flexilev with the OraFID device and app. It will also evaluate the treatment's efficacy, safety, and tolerability.
Frequently Asked Questions
What is A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients?
A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients is a clinical trial registered under NCT07839793. Current status: RECRUITING.
What is the status of NCT07839793?
The current status of NCT07839793 (A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients) is: RECRUITING.
When did A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients start?
A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients started on 2026-05-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.